Trending...
- New York Komedians Presents an Evening of Laughs at Broadway
- Long Beach: Community Invited to Provide Input on Updated Subdivision Ordinance
- SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Funko, Inc. with Losses of $100,000 to Contact the Firm
WEST HOLLYWOOD, Calif. - Californer -- Simufilam is a leading candidate to become the first effective treatment for Alzheimer's Disease. In an analysis by sfbanc financial, Cassava Sciences, Inc. (SAVA) was upgraded as a Strong Buy, from 8/10 to 9.5/10.
The drug in development purportedly works by retiring the proper conformation of filamin A, a molecule involved in the cascade of Alzheimer's disease. Open-label results are showing effectiveness in 84% of subjects treated. These promising results, along with recent insider buying, has led the sfbanc community to upgrade the stock.
More on The Californer
Additional results from the open label trial are expected by the end of this year. Call volume shows optimism for the results of the Cognitive Maintenance Study (CMS) in late 2023. This trial will include 100 subjects randomized to switch from active drug to placebo. Simufilam is currently in two randomized placebo-controlled Phase 3 trials.
sfbanc is a financial community that provides analysis and discussion of available public information in the finance sector. https://sfbanc.com
The drug in development purportedly works by retiring the proper conformation of filamin A, a molecule involved in the cascade of Alzheimer's disease. Open-label results are showing effectiveness in 84% of subjects treated. These promising results, along with recent insider buying, has led the sfbanc community to upgrade the stock.
More on The Californer
- Author/Photographer David Goodman Announces June 27 Release of His New Book An American Cannabis Story
- Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Tingo Group, Inc. (TIO) on Behalf of Investors
- Plustek Technology Streamlining Document Management Case Study
- California: Governor Newsom Proclaims Immigrant Heritage Month 2023
- SimplyCodes Launches AI Plugin for ChatGPT to Provide Real-Time Discount and Shopping Assistance
Additional results from the open label trial are expected by the end of this year. Call volume shows optimism for the results of the Cognitive Maintenance Study (CMS) in late 2023. This trial will include 100 subjects randomized to switch from active drug to placebo. Simufilam is currently in two randomized placebo-controlled Phase 3 trials.
sfbanc is a financial community that provides analysis and discussion of available public information in the finance sector. https://sfbanc.com
Source: sfbanc
Filed Under: Biotech
1 Comment
- J Hautau:
SAVA🚀 no side effects. Promising.
Latest on The Californer
- netElastic Achieves 1 Terabit Throughput on its Leading-Edge vBNG
- Summer Swim Sessions Start Soon At The Simi and Yarrow YMCAs
- Aldelo and Evolv Announce New Strategic Partnership
- From Inmate to Emotional Wellness Children's Book Writer
- AFCC To Launch Rebrand at AIA Conference, Will Become AFC
- Chad Blomgren, U.S. Army Veteran and Gilead Sciences Senior Director, Joins Dream Foundation Board
- Dog Door in Screen Door solution for pet owners
- AIntelligent Studios Agency Launches to Disrupt Marketing
- KYC2020 Offers Free Sanctions Screening for Non-Commercial Use
- Introducing RecipeNFT: The Revolutionary Platform for Preserving Family Recipes on the Avalanche Blockchain
- Introducing Obitz.io: Revolutionizing Obituaries with Blockchain Technology
- ATP is now Veryon: Unveiling a new era of uptime and innovation
- Agent IQ and WBR Insights Release Annual Future Branches Emerging Technology Report
- Introducing Vegan Wines: Ethical and Exquisite Wine Selections for Conscious Consumers
- Bent Danholm of MAXIM Realty Orlando Joins Forces With Tech Company to Improve Target Marketing of Homes in Central Florida
- Voices for Humanity Fights Psychiatric Abuse in Hungary with János Dobos and Klára Hídvégi
- UserGems Sheds Light on Revenue Potential of "Forgotten Champions" in New Research
- World of Sweets Chooses Algonomy's Personalisation Platform to Treat Its B2B Customers to a Taste of 1-1 Personalised Experiences USA - English USA - English
- California: During National Gun Violence Awareness Month, Governor Newsom Launches GunSafety.ca.gov
- Free Job Training and Incentives Now Available for California Caregivers